# A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)

> **NCT00212797** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 273 (actual)

## Conditions studied

- Depression
- Depressive Disorders
- Psychotic Disorders

## Interventions

- **DRUG:** Org 34517
- **DRUG:** Org 34517
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00212797
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 273 (ACTUAL)
- **Last updated:** 2015-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00212797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00212797, "A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00212797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*